BioCentury
ARTICLE | Clinical News

Imprime PGG: Additional Phase IIb data

February 10, 2014 8:00 AM UTC

Additional data from an open-label, international Phase IIb trial in 90 patients with previously untreated advanced NSCLC showed that once-weekly 4 mg/kg IV Imprime PGG plus Erbitux cetuximab, paclitaxel and carboplatin led to an ORR, the primary endpoint, of 48% vs. 23% for Erbitux, paclitaxel and carboplatin alone (p=0.048). Median OS was 10.2 months for Imprime PGG plus Erbitux, paclitaxel and carboplatin vs. 11.2 months for the control arm (p=0.85). Three-year survival rates were 7% for the Imprime PGG arm vs. 0% for the control arm. Imprime PGG was well tolerated. Data were presented at the AACR-IASLC joint meeting in San Diego. Biothera previously reported that Imprime PGG plus Erbitux, paclitaxel and carboplatin met the primary endpoint (see BioCentury, Dec. 9, 2013). Imprime PGG is also in a Phase III trial to treat advanced colorectal cancer and a Phase II trial in combination with Avastin bevacizumab for NSCLC. An interim analysis of the Phase III colorectal cancer trial is expected in 3Q14. ...